Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Data show >90% knockdown of TTR following administration in healthy volunteers Positive safety and tolerability profile for LICA platform-based therapy Phase 3 program on track to start later...
-
Multiple presentations on the long-term efficacy and safety of TEGSEDI® (inotersen) in patients with polyneuropathy caused by hATTR Amyloidosis Topline data results to be presented from the Phase 1...
-
Mean triglyceride levels decreased 77% in volanesorsen-treated patients versus an 18% increase in patients in placebo group Akcea launching WAYLIVRA in the European Union BOSTON and CARLSBAD, Calif,...
-
Achieved Second Quarter 2019 TEGSEDI® (inotersen) Global Net Product Revenues of $10 Million Conference Call Webcast Tuesday, August 6, 4:30 p.m. ET at www.akceatx.com BOSTON, Aug. 06, 2019 (GLOBE...
-
BOSTON, Mass. and CARLSBAD, Calif., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ:...
-
BOSTON, July 29, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (Nasdaq:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on Tuesday, August 6th...
-
BOSTON and Aliso Viejo, Calif., July 16, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (Nasdaq:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ambry Genetics Corporation (“Ambry”), a...
-
BOSTON and CARLSBAD, Calif., June 26, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS),...
-
BOSTON and CARLSBAD, Calif., June 20, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS),...
-
BOSTON, May 28, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with...